
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a United States-based company in the Healthcare sector with a market capitalisation of $50.3B. Its FinScore is 69/100; its highest-scoring layer is Quality (86) and its lowest is Value (36). The shares trade at 49.7x trailing earnings and are up 1% year to date.
Share price performance
About Edwards Lifesciences Corporation
www.edwards.comEdwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- HQ
- United States
- Fiscal year-end
- December
- Trading currency
- USD
- Reporting currency
- USD
- Fundamentals updated
- 87 days ago
- Market cap
- $50.3B
- Shares outstanding
- 576.4M
- P/E (TTM)
- 49.7x
- Beta (issuer)
- 0.86
- Revenue (latest FY)
- $6.1B
Revenue breakdown
- Transcatheter Heart Valves74.0%$4.5B
- Surgical Heart Valve Therapy17.0%$1.0B
- Transcatheter Mitral And Tricuspid Therapies9.1%$550.6M
FinScore
As of 2026-10-19Snapshot
Ownership
As of 2026-06-30Sign up or log in to see Analysis
Analysis for Edwards Lifesciences Corporation is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Financials
Financials for Edwards Lifesciences Corporation is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Estimates
Estimates for Edwards Lifesciences Corporation is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Peers
Peers for Edwards Lifesciences Corporation is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Valuation
Valuation for Edwards Lifesciences Corporation is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see News
News for Edwards Lifesciences Corporation is available to Finryse members. The Overview stays open to everyone; creating an account is free.